The combined company has annual pro forma revenues of more than $23 billion anticipated in 2015. Additionally, it intends to invest approximately $1.7 billion in research and development in 2015.
“The combination of Actavis and Allergan creates an exceptional global pharmaceutical company and a leader in a new industry model — Growth Pharma,” said Brent Saunders, CEO and president of Actavis.
More articles on GI/endoscopy:
AGA: Young investigators award deadline extended
4 new GI centers & partnerships
New HCV pills drive U.S. drug spending up 13.1%
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.